HomeTOP STORIESSage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress By rogerjudd April 30, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleFirst solar outlines $12.50 to $17.50 EPS guidance for 2025 amid tariff challengesNext articleEnova international forecasts 20% revenue growth for Q2 2025 amid strong SMB performance latest articles The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds explore more The inflation process has shifted even as headline CPI declined – Federal Reserve Cerrado Gold reports Q4 results As H-1B Visa Program Changes, Skilled Foreign Workers Consider Leaving U.S. They Get Drunk Without Drinking: What It’s Like to Have Auto-brewery Syndrome Parents Who Borrowed for Children’s College Face Looming Deadline Watch: Artemis II’s journey so far… in 85 seconds
